Combined Amelioration of Ginsenoside (Rg1, Rb1 and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Liver Disease
Combined Amelioration of Ginsenoside (Rg1, Rb1 and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-alcoholic Liver Disease
复制标题
DOI：
10.2174/1389201020666190311143554
复制
发表时间：
2019-01-01
影响因子：
2.8
通讯作者：
Eom, Dae-Woon
中科院分区：
文献类型：
--
作者：
Kim, Jin-Chul;Jeon, Joo-Yeong;Eom, Dae-Woon
背景：红参是一种传统药物，已用于治疗多种代谢性疾病和炎症性疾病。益生菌给药已被证实对非酒精性脂肪性肝病 (NAFLD) 具有有益作用。本研究的目的是确定与每种单独产品报告的效果相比，韩国红参 (KRG) 和益生菌的组合是否可以协同减少 NAFLD 和肝脏炎症。方法：分别给 db/db 和 C57BL/6 小鼠喂食正常饮食和高脂饮食 (HFD)，并用 KRG、益生菌或两者治疗。检查样品的脂质含量、激酶蛋白磷酸化和基因表达模式。结果：与未治疗的对照小鼠相比，KRG 和益生菌治疗的 HFD 喂养小鼠体重减轻，炎症细胞因子分泌减少。同样的治疗在改善 db/db 小鼠的 NAFLD 参数方面不太成功，而两种产品的组合并没有增强其治疗潜力。结论：本研究的结果表明，KRG 和益生菌给药通过减少体重增加和肝脏炎症，改善血脂异常小鼠模型中的 NAFLD 症状。两种产品的共同给药并没有增强其功效，应进行进一步的研究以阐明其作用机制。
Background: Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product.Method: db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns.Results: KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential.Conclusion: The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadministration of both products did not enhance their efficacy, and further research should be conducted to clarify their mechanisms of action.